3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
39
Myelodysplastic Syndromes
15
Leukemia, Myelomonocytic, Chronic
11
Leukemia
4
Myeloproliferative Disorders
3
Anemia, Refractory, with Excess of Blasts
3
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Sarcoma
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
pembrolizumab
2
venetoclax
1
taxane
1
sargramostim
1
rucaparib
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
Platinum
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Capecitabine
1
Azacitidine
1
Antimetabolites
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pathologic Complete Response
×
Azacitidine
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled